Carbamazepine
- Generic Name
- Carbamazepine
- Brand Names
- Carbatrol, Carnexiv, Epitol, Equetro, Tegretol
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12N2O
- CAS Number
- 298-46-4
- Unique Ingredient Identifier
- 33CM23913M
- Background
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant use...
- Indication
Carbamazepine is indicated for the treatment of epilepsy and pain associated with true trigeminal neuralgia. In particular, carbamazepine has shown efficacy in treating mixed seizures, partial seizures with complex symptoms, and generalized tonic-clonic seizures. Carbamazepine is also indicated for the treatment of manic episodes and mixed manic-depressive e...
- Associated Conditions
- Acute Mania, Alcohol Withdrawal Syndrome, Complex Partial Seizure Disorder, Generalized Tonic-Clonic Seizures, Mixed manic depressive episode, Pain, Partial Seizures With Secondary Generalization, Restless Legs Syndrome (RLS)
- Associated Therapies
- -
Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2008-05-30
- Lead Sponsor
- Scienze Neurologiche Ospedaliere
- Target Recruit Count
- 630
- Registration Number
- NCT00542802
- Locations
- 🇮🇹
Ospedale Civico, Palermo, Italy
🇮🇹Ospedale S. Giacomo, Novi Ligure, AL, Italy
🇮🇹Ospedale S. Croce E Carle, Cuneo, CN, Italy
A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 583
- Registration Number
- NCT00477295
Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs
- Conditions
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 361
- Registration Number
- NCT00438451
- Locations
- 🇩🇪
Department of Neurology, University of Mainz Medical Centre, Mainz, Germany
Prediction of Childhood Epilepsy Outcome in Bangladesh
- Conditions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2006-12-25
- Lead Sponsor
- Institute of Child Health
- Target Recruit Count
- 92
- Registration Number
- NCT00381537
- Locations
- 🇬🇧
Institute of Child Health, London, United Kingdom
🇧🇩Children's Hospital Dhaka (Shishu) Bangladesh., Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 139
- Registration Number
- NCT00266630
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Second-Line Treatment Choice for Epilepsy
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-09-12
- Lead Sponsor
- Dutch Epilepsy Clinics Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00208520
- Locations
- 🇳🇱
Dutch Epilepsy Clinics Foundation, Zwolle, Netherlands
Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-05-16
- Lead Sponsor
- Centre of Chinese Medicine, Georgia
- Target Recruit Count
- 65
- Registration Number
- NCT00207428
Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00190892
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Petersburg, Russian Federation
Study of Efficacy of Carbamazepine in Therapy of Patients With Moderate Persistent and Severe Bronchial Asthma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Centre of Chinese Medicine, Georgia
- Target Recruit Count
- 68
- Registration Number
- NCT00153296
Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.
- Conditions
- First Posted Date
- 2001-01-04
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 720
- Registration Number
- NCT00007670
- Locations
- 🇺🇸
Bronx VA Medical Center, Bronx, New York, United States
🇺🇸Edward Hines Jr. VA Hospital, Hines, Illinois, United States
🇺🇸Birmingham VA Medical Center, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.